Condition: BCLC Stage C Hepatocellular Carcinoma · Chemotherapy Effect · Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
This description comes directly from the study's public registry record.
Yunxiuxiu Xu, MD · 17722864609 · xuyxx@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06172205